Key facts
- This page summarizes Laura A. Philips's Form 4 filing for Niki BioSolutions, Inc. (NIKI).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 21 Oct 2026, 16:51.
Laura A. Philips - 22 Jul 2026 Form 4 Insider Report for Niki BioSolutions, Inc. (NIKI)
- Reporting relationship
- Director
- Issuer ticker
- NIKI
- Reported as of
- 22 Jul 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Oct 2026, 16:51:47 UTC
- Prior SEC filing
- 24 Jul 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Laura A. Philips
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Laura A. Philips filed Form 4 for Niki BioSolutions, Inc. (NIKI) on 21 Oct 2026.
Change
- Previous filing in this sequence was filed on 24 Jul 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001401312
Primary reporting owner
Philips Laura A
- Relationship
- Director
- Address
- 116 VILLAGE BOULEVARD, SUITE 200, PRINCETON
- Signature
- /s/ Laura A. Philips
- Signature date
- 21 Oct 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NIKI
transaction
Derivative
Stock Options
Award
- Transaction value
- Shares
- +8,000
- Change %
- Price
- $0.000000*
- Shares after
- 8,000
- Date
- 22 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,000
- Exercise price
- $8.83
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The options vest as follows: (i) 2,000 options vested immediately upon the closing of the merger; and (ii) the remaining 6,000 options vest in three equal quarterly installments of 2,000 options each, commencing on the first business day of the first full quarter following the effective date of the merger.